{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:38:30Z","timestamp":1784029110897,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","award":["IP2015 089474"],"award-info":[{"award-number":["IP2015 089474"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/1-156-04\/503-11-001"],"award-info":[{"award-number":["503\/1-156-04\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s43440-023-00566-1","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:03:12Z","timestamp":1705590192000},"page":"112-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of bidirectional communication between the adipokines and the endogenous opioid system in an experimental mouse model of colitis-associated colorectal cancer"],"prefix":"10.1007","volume":"76","author":[{"given":"Agata","family":"Szymaszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"Mierzejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Januszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Machelak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Talar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"W\u0142odarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"\u015awierczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radzis\u0142aw","family":"Kordek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Fichna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-1948","authenticated-orcid":false,"given":"Marta","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"3","key":"566_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3892\/or.2015.4108","volume":"34","author":"M De Rosa","year":"2015","unstructured":"De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, et al. Genetics, diagnosis and management of colorectal cancer (review). Oncol Rep. 2015;34(3):1087\u201396.","journal-title":"Oncol Rep"},{"issue":"suppl_2","key":"566_CR2","doi-asserted-by":"publisher","first-page":"S362","DOI":"10.2337\/dc09-S340","volume":"32","author":"E Esteve","year":"2009","unstructured":"Esteve E, Ricart W, Fern\u00e1ndez-Real JM. Adipocytokines and insulin resistance. Diabetes Care. 2009;32(suppl_2):S362\u20137.","journal-title":"Diabetes Care"},{"issue":"3","key":"566_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(14)70134-2","volume":"3","author":"AJ Cox","year":"2015","unstructured":"Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3(3):207\u201315.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"566_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11864-019-0699-1","volume":"21","author":"A Szczepaniak","year":"2020","unstructured":"Szczepaniak A, Fichna J, Zieli\u0144ska M. Opioids in cancer development, progression and metastasis: focus on colorectal cancer. Curr Treat Options Oncol. 2020;21(1):6.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"566_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/MED.0000000000000219","volume":"23","author":"P Mosi\u0144ska","year":"2016","unstructured":"Mosi\u0144ska P, Zieli\u0144ska M, Fichna J. Expression and physiology of opioid receptors in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2016;23(1):3\u201310.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"566_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","volume":"49","author":"M Sobczak","year":"2014","unstructured":"Sobczak M, Sa\u0142aga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol. 2014;49(1):24\u201345.","journal-title":"J Gastroenterol"},{"issue":"2","key":"566_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/SPC.0000000000000208","volume":"10","author":"T Wigmore","year":"2016","unstructured":"Wigmore T, Farquhar-Smith P. Opioids and cancer: friend or foe? Curr Opin Support Palliat Care. 2016;10(2):109\u201318.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1\u20132","key":"566_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0304-3835(02)00360-9","volume":"187","author":"Y Harimaya","year":"2002","unstructured":"Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26\u2013L5 carcinoma cells. Cancer Lett. 2002;187(1\u20132):121\u20137.","journal-title":"Cancer Lett"},{"key":"566_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119524","volume":"278","author":"D Chakraborty","year":"2021","unstructured":"Chakraborty D, Jin W, Wang J. The bifurcated role of adiponectin in colorectal cancer. Life Sci. 2021;278: 119524.","journal-title":"Life Sci"},{"key":"566_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118507","volume":"262","author":"D Chakraborty","year":"2020","unstructured":"Chakraborty D, Wang J. Nonalcoholic fatty liver disease and colorectal cancer: correlation and missing links. Life Sci. 2020;262: 118507.","journal-title":"Life Sci"},{"issue":"3","key":"566_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2337\/dc14-1175","volume":"38","author":"PJHL Peeters","year":"2015","unstructured":"Peeters PJHL, Bazelier MT, Leufkens HGM, de Vries F, De Bruin ML. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care. 2015;38(3):495\u2013502.","journal-title":"Diabetes Care"},{"issue":"11","key":"566_CR12","doi-asserted-by":"publisher","first-page":"18456","DOI":"10.18632\/oncotarget.14472","volume":"8","author":"N Gonz\u00e1lez","year":"2017","unstructured":"Diabetes Cancer Connect Consortium, Gonz\u00e1lez N, Prieto I, del Puerto-Nevado L, Portal-Nu\u00f1ez S, Ardura JA, et al. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget. 2017;8(11):18456\u201385.","journal-title":"Oncotarget"},{"issue":"11","key":"566_CR13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/mc.22428","volume":"55","author":"L Cai","year":"2016","unstructured":"Cai L, Xu S, Piao C, Qiu S, Li H, Du J. Adiponectin induces CXCL1 secretion from cancer cells and promotes tumor angiogenesis by inducing stromal fibroblast senescence: APN INDUCES CXCL1 SECRETION FROM TUMOR CELL. Mol Carcinog. 2016;55(11):1796\u2013806.","journal-title":"Mol Carcinog"},{"issue":"30","key":"566_CR14","doi-asserted-by":"publisher","first-page":"48671","DOI":"10.18632\/oncotarget.8932","volume":"7","author":"T Wei","year":"2016","unstructured":"Wei T, Ye P, Peng X, Wu LL, Yu GY. Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies. Oncotarget. 2016;7(30):48671\u201391.","journal-title":"Oncotarget"},{"issue":"2","key":"566_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CEJ.0b013e32834c9b55","volume":"21","author":"W An","year":"2012","unstructured":"An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21(2):126\u201333.","journal-title":"Eur J Cancer Prev"},{"issue":"1B","key":"566_CR16","first-page":"483","volume":"27","author":"P Ferroni","year":"2007","unstructured":"Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O, Roselli M, Guadagni F. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res. 2007;27(1B):483\u20139.","journal-title":"Anticancer Res"},{"issue":"44","key":"566_CR17","doi-asserted-by":"publisher","first-page":"11682","DOI":"10.1021\/bi801451f","volume":"47","author":"MH Lee","year":"2008","unstructured":"Lee MH, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM. The adiponectin receptors AdipoR1 and AdipoR2 activate ERK1\/2 through a Src\/Ras-dependent pathway and stimulate cell growth. Biochemistry. 2008;47(44):11682\u201392.","journal-title":"Biochemistry"},{"issue":"5","key":"566_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/ncb1404","volume":"8","author":"X Mao","year":"2006","unstructured":"Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516\u201323.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"566_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nm1557","volume":"13","author":"T Yamauchi","year":"2007","unstructured":"Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332\u20139.","journal-title":"Nat Med"},{"issue":"11","key":"566_CR20","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.3390\/ijms22115569","volume":"22","author":"E Nigro","year":"2021","unstructured":"Nigro E, Daniele A, Salzillo A, Ragone A, Naviglio S, Sapio L. AdipoRon and other adiponectin receptor agonists as potential candidates in cancer treatments. Int J Mol Sci. 2021;22(11):5569.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"566_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1874467212666191022102800","volume":"13","author":"IA Bhat","year":"2020","unstructured":"Bhat IA, Kabeer SW, Reza MI, Mir RH, Dar MO. AdipoRon: a novel insulin sensitizer in various complications and the underlying mechanisms: a review. Curr Mol Pharmacol. 2020;13(2):94\u2013107.","journal-title":"Curr Mol Pharmacol"},{"issue":"10","key":"566_CR22","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.3390\/molecules26102946","volume":"26","author":"H Zatorski","year":"2021","unstructured":"Zatorski H, Salaga M, Zieli\u0144ska M, Majchrzak K, Binienda A, Kordek R, et al. AdipoRon, an orally active, synthetic agonist of AdipoR1 and AdipoR2 receptors has gastroprotective effect in experimentally induced gastric ulcers in mice. Molecules. 2021;26(10):2946.","journal-title":"Molecules"},{"issue":"22","key":"566_CR23","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/jnci\/dji376","volume":"97","author":"EK Wei","year":"2005","unstructured":"Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. JNCI J Natl Cancer Inst. 2005;97(22):1688\u201394.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"566_CR24","first-page":"171","volume":"28","author":"SJ Wang","year":"2020","unstructured":"Wang SJ, Wang C, Wang WQ, Hao QQ, Liu YF. Adiponectin receptor agonist AdipoRon inhibits the proliferation of myeloma cells via the ampk\/autophagy pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(1):171\u20136.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"20","key":"566_CR25","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1101\/gad.306092.117","volume":"31","author":"L Wang","year":"2017","unstructured":"Wang L, Collings CK, Zhao Z, Cozzolino KA, Ma Q, Liang K, et al. A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism. Genes Dev. 2017;31(20):2056\u201366.","journal-title":"Genes Dev"},{"issue":"1\u20132","key":"566_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11010-019-03586-9","volume":"461","author":"AA Ramzan","year":"2019","unstructured":"Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019;461(1\u20132):37\u201346.","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"566_CR27","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1007\/s13277-015-3911-3","volume":"36","author":"S Malih","year":"2015","unstructured":"Malih S, Najafi R. AdipoRon: a possible drug for colorectal cancer prevention? Tumor Biol. 2015;36(9):6673\u20135.","journal-title":"Tumor Biol"},{"key":"566_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173463","volume":"885","author":"M Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska M, Szymaszkiewicz A, Jacenik D, Schodel L, Sa\u0142aga M, Zatorski H, et al. Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice. Eur J Pharmacol. 2020;885: 173463.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"566_CR29","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.3390\/jcm11102739","volume":"11","author":"R Modesto","year":"2022","unstructured":"Modesto R, Estarreja J, Silva I, Rocha J, Pinto R, Mateus V. Chemically induced colitis-associated cancer models in rodents for pharmacological modulation: a systematic review. J Clin Med. 2022;11(10):2739.","journal-title":"J Clin Med"},{"issue":"24","key":"566_CR30","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/0024-3205(85)90322-4","volume":"36","author":"BC Yoburn","year":"1985","unstructured":"Yoburn BC, Goodman RR, Cohen AH, Pasternak GW, Inturrisi CE. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Life Sci. 1985;36(24):2325\u201332.","journal-title":"Life Sci"},{"issue":"2","key":"566_CR31","first-page":"439","volume":"232","author":"A Tempel","year":"1985","unstructured":"Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther. 1985;232(2):439.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"566_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0304-3835(96)04119-5","volume":"101","author":"SD Hytrek","year":"1996","unstructured":"Hytrek SD, McLaughlin PJ, Lang CM, Zagon IS. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett. 1996;101(2):159\u201364.","journal-title":"Cancer Lett"},{"issue":"1","key":"566_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jnci\/78.1.141","volume":"78","author":"IS Zagon","year":"1987","unstructured":"Zagon IS, McLaughlin PJ. Modulation of murine neuroblastoma in nude mice by opioid antagonists2. JNCI J Natl Cancer Inst. 1987;78(1):141\u20137.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"566_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.intimp.2018.05.020","volume":"61","author":"Z Li","year":"2018","unstructured":"Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018;61:178\u201384.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"566_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bcp.2015.06.016","volume":"97","author":"PJ McLaughlin","year":"2015","unstructured":"McLaughlin PJ, Zagon IS. Duration of opioid receptor blockade determines biotherapeutic response. Biochem Pharmacol. 2015;97(3):236\u201346.","journal-title":"Biochem Pharmacol"},{"issue":"4611","key":"566_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1126\/science.6867737","volume":"221","author":"IS Zagon","year":"1983","unstructured":"Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671\u20133.","journal-title":"Science"},{"key":"566_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104614","volume":"152","author":"S Leone","year":"2020","unstructured":"Leone S, Chiavaroli A, Recinella L, Di Valerio V, Veschi S, Gasparo I, et al. Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis. Pharmacol Res. 2020;152: 104614.","journal-title":"Pharmacol Res"},{"issue":"5","key":"566_CR38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/carcin\/bgn080","volume":"29","author":"S Miyamoto","year":"2008","unstructured":"Miyamoto S, Yasui Y, Tanaka T, Ohigashi H, Murakami A. Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice. Carcinogenesis. 2008;29(5):1057\u201363.","journal-title":"Carcinogenesis"},{"issue":"4","key":"566_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1751-2980.2011.00504.x","volume":"12","author":"XT Xu","year":"2011","unstructured":"Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma: adiponectin and colorectal neoplasm. J Dig Dis. 2011;12(4):234\u201344.","journal-title":"J Dig Dis"},{"issue":"1","key":"566_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/1471-2407-14-811","volume":"14","author":"CH Tae","year":"2014","unstructured":"Tae CH, Kim SE, Jung SA, Joo YH, Shim KN, Jung HK, et al. Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC Cancer. 2014;14(1):811.","journal-title":"BMC Cancer"},{"issue":"2","key":"566_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00595-016-1334-4","volume":"47","author":"K Otani","year":"2017","unstructured":"Otani K, Ishihara S, Yamaguchi H, Murono K, Yasuda K, Nishikawa T, et al. Adiponectin and colorectal cancer. Surg Today. 2017;47(2):151\u20138.","journal-title":"Surg Today"},{"issue":"07","key":"566_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4149\/BLL_2013_083","volume":"114","author":"F Kosova","year":"2013","unstructured":"Kosova F, Coskun T, Kaya Y, Kara E, Ari Z. Adipocytokine levels of colon cancer patients before and after treatment. Bratisl Med J. 2013;114(07):394\u20137.","journal-title":"Bratisl Med J"},{"issue":"1","key":"566_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7314\/APJCP.2015.16.1.367","volume":"16","author":"T Ayyildiz","year":"2015","unstructured":"Ayyildiz T, Dolar E, Ugras N, Eminler AT, Erturk B, Adim SB, et al. Adipo-R1 and Adipo-R2 expression in colorectal adenomas and carcinomas. Asian Pac J Cancer Prev. 2015;16(1):367\u201372.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"566_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/phpp.12290","volume":"33","author":"K Hiramoto","year":"2017","unstructured":"Hiramoto K, Yokoyama S, Yamate Y. Ultraviolet A eye irradiation ameliorates colon carcinoma induced by azoxymethane and dextran sodium sulfate through \u03b2-endorphin and methionine-enkephalin. Photodermatol Photoimmunol Photomed. 2017;33(2):84\u201391.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"566_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1677\/ERC-07-0197","volume":"15","author":"CJ Williams","year":"2008","unstructured":"Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, et al. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer. 2008;15(1):289\u201399.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"566_CR46","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/cancers10100348","volume":"10","author":"W Nasry","year":"2018","unstructured":"Nasry W, Rodriguez-Lecompte J, Martin C. Role of COX-2\/PGE2 mediated inflammation in oral squamous cell carcinoma. Cancers. 2018;10(10):348.","journal-title":"Cancers"},{"issue":"2","key":"566_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cells5020015","volume":"5","author":"M Park","year":"2016","unstructured":"Park M, Hong J. Roles of NF-\u03baB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 2016;5(2):15.","journal-title":"Cells"},{"issue":"8","key":"566_CR48","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3389\/fimmu.2017.01373","volume":"25","author":"J Kempski","year":"2017","unstructured":"Kempski J, Brockmann L, Gagliani N, Huber S. TH17 cell and epithelial cell crosstalk during inflammatory bowel disease and carcinogenesis. Front Immunol. 2017;25(8):1373.","journal-title":"Front Immunol"},{"key":"566_CR49","series-title":"Advances in experimental medicine and biology","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-0348-0837-8_2","volume-title":"Inflammation and cancer","author":"NB Janakiram","year":"2014","unstructured":"Janakiram NB, Rao CV. The role of inflammation in colon cancer. In: Aggarwal BB, Sung B, Gupta SC, editors. Inflammation and cancer, vol. 816. Advances in experimental medicine and biology. Basel: Springer; 2014. p. 25\u201352. https:\/\/doi.org\/10.1007\/978-3-0348-0837-8_2."},{"issue":"10","key":"566_CR50","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/sj.bjc.6600927","volume":"88","author":"MP Charalambous","year":"2003","unstructured":"The Colorectal Cancer Study Group, Charalambous MP, Maih\u00f6fner C, Bhambra U, Lightfoot T, Gooderham NJ. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-\u03baB and I\u03baB kinase-\u03b1 in human colorectal cancer epithelial cells. Br J Cancer. 2003;88(10):1598\u2013604.","journal-title":"Br J Cancer"},{"issue":"7","key":"566_CR51","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-08-1383","volume":"15","author":"K Sakamoto","year":"2009","unstructured":"Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, et al. Constitutive NF-\u03baB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res. 2009;15(7):2248\u201358.","journal-title":"Clin Cancer Res"},{"issue":"S1","key":"566_CR52","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1017\/S0007114507838050","volume":"98","author":"A Gil","year":"2007","unstructured":"Gil A, Mar\u00eda Aguilera C, Gil-Campos M, Ca\u00f1ete R. Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. Br J Nutr. 2007;98(S1):S121\u20136.","journal-title":"Br J Nutr"},{"issue":"50","key":"566_CR53","doi-asserted-by":"publisher","first-page":"50810","DOI":"10.1074\/jbc.M309469200","volume":"278","author":"TS Tsao","year":"2003","unstructured":"Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, et al. Role of disulfide bonds in Acrp30\/adiponectin structure and signaling specificity. J Biol Chem. 2003;278(50):50810\u20137.","journal-title":"J Biol Chem"},{"issue":"13","key":"566_CR54","first-page":"3632","volume":"63","author":"W Liu","year":"2003","unstructured":"Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, Jung YD, Fan F, Takeda A, Akagi M, Bar-Eli M, Gallick GE, Ellis LM. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 2003;63(13):3632\u20136.","journal-title":"Cancer Res"},{"issue":"4","key":"566_CR55","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1078-0432.CCR-05-1603","volume":"12","author":"DM Elaraj","year":"2006","unstructured":"Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res. 2006;12(4):1088\u201396.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"566_CR56","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/diagnostics11081382","volume":"11","author":"OM Koper-Lenkiewicz","year":"2021","unstructured":"Koper-Lenkiewicz OM, Dymicka-Piekarska V, Milewska AJ, Zi\u0144czuk J, Kami\u0144ska J. The relationship between inflammation markers (CRP, IL-6, sCD40L) and colorectal cancer stage, grade, size and location. Diagnostics. 2021;11(8):1382.","journal-title":"Diagnostics"},{"issue":"77","key":"566_CR57","first-page":"1407","volume":"54","author":"V Dymicka-Piekarska","year":"2007","unstructured":"Dymicka-Piekarska V, Kemona H, Guzinska-Ustymowicz K. Does surgery affect certain mediators of thrombocytopoiesis in patients with colorectal cancer? Hepatogastroenterology. 2007;54(77):1407\u201311.","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"566_CR58","first-page":"113","volume":"21","author":"AC Tsamandas","year":"2007","unstructured":"Tsamandas AC, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T, Kalofonos H, Vagianos CE, Scopa CD. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients\u2019 outcome. In Vivo. 2007;21(1):113\u20138 (Erratum in: In Vivo. 2007 May-Jun;21(3):553. Zolota, V; Vassiliou, V; Matatsoris, T. Erratum in: In Vivo. 2007 Nov-Dec;21(6):1172).","journal-title":"In Vivo"},{"issue":"10","key":"566_CR59","first-page":"2422","volume":"56","author":"M Krajewska","year":"1996","unstructured":"Krajewska M, Krajewski S, Holt R. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 1996;56(10):2422\u20137.","journal-title":"Cancer Res"},{"issue":"8","key":"566_CR60","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/bjc.1996.178","volume":"73","author":"A Watson","year":"1996","unstructured":"Watson A, Merritt A, Jones L, Askew J, Anderson E, Becciolini A, et al. Evidence for reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer. 1996;73(8):889\u201395.","journal-title":"Br J Cancer"},{"issue":"4","key":"566_CR61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5114\/pg.2018.79813","volume":"13","author":"M Brzozowa-Zasada","year":"2018","unstructured":"Brzozowa-Zasada M, Kurek J, Piecuch A, St\u0119plewska K. Correlation study of GAPDH, Bcl-2, and Bax protein immunoexpression in patients with colorectal adenocarcinoma. Gastroenterol Rev. 2018;13(4):322\u201331.","journal-title":"Gastroenterol Rev"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-023-00566-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T02:36:48Z","timestamp":1706755008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-023-00566-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1007\/s43440-023-00566-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}